Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan in THP-Insensitive HER2-Positive Early Breast Cancer
NCT07647263Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Mar 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer, sponsored by First Affiliated Hospital of Soochow University. Started Mar 2026; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07647263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647263.